Key points are not available for this paper at this time.
Background: Chronic Kidney Disease (CKD) patients undergoing hemodialysis usually undergo anemia condition. Calculation of hemoglobin and other hematological parameters such as Ret-he (Reticulocyte Hemoglobin) and reticulocytes along with Glomerulus Filtration Rate (GFR) calculations determine the stage of CKD. Erythropoietin (EPO) administration is one of the important therapies for CKD patients. Initiation of EPO therapy, according to Kidney Disease Improving Global Outcome (KDIGO). Method: This study was an observational cross-sectional analytical study. This research was carried out from October 2023 to November 2023 at the Hemodialysis Installation of Dr. RSUD. R Sosodoro Djatikoesoemo Bojonegoro. Normality of the data using the Shapiro-Wilk test and differences in Ret-he levels, reticulocyte counts, and hemoglobin levels pre and post-administration of erythropoietin using paired t-test was used if the data were normally distributed and the Wilcoxon test if the data were not normally distributed. Results: This study results showed that there was an increase in ret-he levels pre and post-administration of erythropoietin with pre mean value of 30.50 ± 4.043 and post mean value was 32.20 ± 2.936. Reticulocyte levels also increase pre and post-administration of erythropoietin with a mean value of 1.63 ± 0.869 for pre-administration and 2.04 ± 0.915 for post-administration. Hemoglobin levels before giving erythropoietin with a value of 8.21 ± 0.855 and after giving erythropoietin the value was slightly increased to 8.29 ± 0.853. Rethe and reticulocytes were significant differences between pre and post-EPO administration with p=0.000 and hemoglobin showed that there are no significant difference values pre and post-EPO with p=0.373. Conclusion: There is a significant difference (p-value 0.000) between Ret-He and Reticulocyte levels pre and post-erythropoietin treatment and there is no significant difference (p-value 0.373) Hemoglobin levels pre and post-erythropoietin treatment.
LUKITO et al. (Mon,) studied this question.